Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq ...

Increase in prevalence of autoimmune diseases, rise in technological advancements, and rise in awareness about early diagnosis are the major factors which drive the global market growth. Increasing ...

According to industry analysis, increasing cases of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, celiac disease, and other chronic autoimmune conditions are driving testing ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. “We've always said that acquiring local laboratories or ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

Add Yahoo as a preferred source to see more of our stories on Google. Autoimmune diseases are on the rise. It’s not just a hunch—autoimmune diseases are rising sharply, and the numbers are too ...

BURLINGTON, N.C.--(BUSINESS WIRE)-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and ...

Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company continued expanding adoption of its AVISE CTD testing platform. ・Exagen Inc.

The test that they developed allows detection at the earliest signs of the immune system assault against the pancreas, which is an advantage because most patients being tested for type 1 diabetes are ...

Autoimmune neurological disorders occur when the body's immune system mistakenly attacks healthy tissues within the brain, ...